Cancer News

Vectibix® Improves Survival in Colorectal Cancer, Demonstrates Importance of Tissue Testing (01/28/2016)

The addition of Vectibix® (panitumumab) to best supportive care improves survival over best standard care alone among colorectal cancer patients who have stopped responding to chemotherapy. However, the benefit is only seen with patients who have no RAS mutations, or those with only the KRAS exon 2 mutation. These results were recently presented at the … Continue reading "Vectibix® Improves Survival in Colorectal Cancer, Demonstrates Importance of Tissue Testing"